Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (391-400 of 520) with videos related to

Pageof 52
Sort By:
European Journal of Heart Failure|September 24, 2024
Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudyXiaowen Wang, Maria A Pabon, Maja Cikes, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
Journal of the American College of Cardiology|March 27, 2024
Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
ESC Heart Failure|October 9, 2023
Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartanJawad H Butt, Kirsty McDowell, Toru Kondo, et al.
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
JACC. Heart Failure|June 6, 2024
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m<sup>2</sup>Safia Chatur, Iris E Beldhuis, Brian L Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
Circulation|September 9, 2022
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic SubstudyAmil M Shah, Brian Claggett, Narayana Prasad, et al.
Circulation|November 20, 2014
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fractionSøren L Kristensen, Lars Køber, Pardeep S Jhund, et al.
Pageof 52

Showing results (391-400 of 520) with videos related to

Sort By:
Pageof 52
European Journal of Heart Failure|September 24, 2024
Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE-MI echocardiographic substudyXiaowen Wang, Maria A Pabon, Maja Cikes, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Circulation. Genomic and Precision Medicine|April 2, 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular MedicineDavid Rhainds, Chris J Packard, Mathieu R Brodeur, et al.
Journal of the American College of Cardiology|March 27, 2024
Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
ESC Heart Failure|October 9, 2023
Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartanJawad H Butt, Kirsty McDowell, Toru Kondo, et al.
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
JACC. Heart Failure|June 6, 2024
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m<sup>2</sup>Safia Chatur, Iris E Beldhuis, Brian L Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
Circulation|September 9, 2022
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic SubstudyAmil M Shah, Brian Claggett, Narayana Prasad, et al.
Circulation|November 20, 2014
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fractionSøren L Kristensen, Lars Køber, Pardeep S Jhund, et al.
Pageof 52